-
<![CDATA[FDA Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes]]>
13 Nov 2025 20:22 GMT
… with HER2-positive metastatic breast cancer who have not … treatment regimen for early breast cancer.
in combination with … pertuzumab in patients with breast cancer also informed the approval … combination with trastuzumab and paclitaxel following 4 cycles …
-
<![CDATA[Sacituzumab Govitecan Misses PFS End Point in Metastatic Breast Cancer]]>
11 Nov 2025 21:08 GMT
… this breast cancer population.
“[HR-positive, HER2-negative] metastatic breast cancer is … and HER2-negative metastatic breast cancer following prior endocrine therapy. … choice of capecitabine, paclitaxel, or nab-paclitaxel. Study treatment continued …
-
Health-Related Physical Fitness Status and Associated Factors in Breast Cancer Patients Undergoing Chemotherapy: A Cross-Sectional Study
11 Nov 2025 07:13 GMT
… Breast Cancer Patients
The HRPF parameters of 230 breast cancer … endurance in breast cancer patients undergoing chemotherapy … caused by paclitaxel chemotherapy in breast cancer patients. … subtypes of postmenopausal breast cancer. Breast Cancer Res. 2023; …
-
Gilead announces phase 3 ASCENT─07 study of Trodelvy versus chemotherapy to treat post─endocrine therapy in HR+/HER2─negative metastatic breast cancer fails to meet the primary endpoint of PFS
10 Nov 2025 07:59 GMT
… ;HER2-negative metastatic breast cancer is a highly heterogeneous … metastatic triple-negative breast cancer (TNBC). Trodelvy … including capecitabine, paclitaxel and nab-paclitaxel. Treatment continued … metastatic triple-negative breast cancer (mTNBC) who …
-
Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs
16 Nov 2025 19:56 GMT
… for its lead program, a breast cancer drug that could offer advantages … the presentation, Iambic announced a breast cancer research collaboration with Jazz Pharmaceuticals … called “PIKTOR,” alongside the chemotherapy paclitaxel as a treatment for endometrial …
-
<![CDATA[Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer]]>
07 Nov 2025 23:44 GMT
… “HR+/HER2[–] metastatic breast cancer is a highly heterogeneous disease … including paclitaxel, nab-paclitaxel, or capecitabine.
Sacituzumab Govitecan in Breast Cancer
Despite … HR+/HER2-) metastatic breast cancer who have received endocrine therapy …
-
<![CDATA[First-Line Sacituzumab Govitecan After Endocrine Therapy Fails to Improve PFS in HR+/HER2-Negative Breast Cancer ]]>
07 Nov 2025 17:32 GMT
… HER2-negative metastatic breast cancer, missing the primary … hybridization) metastatic breast cancer who had received … included capecitabine, paclitaxel, or nab-paclitaxel (Abraxane). Treatment … HER2-negative metastatic breast cancer.
Sacituzumab govitecan is …
-
Circuit Weight Training Enhances Quality of Life and Functional Outcomes in Breast Cancer Survivors: A Randomized Controlled Trial
07 Nov 2025 16:14 GMT
… breast cancer sufferers in the US alone.4
Breast cancer … genotypes in paclitaxel-treated premenopausal breast cancer patients. Scient … parameters in breast cancer patients undergoing neurotoxic … ’ impact on breast cancer survivors’ functional performance …
-
Pharmacophore modeling nets paclitaxel potentiator
11 Nov 2025 01:12 GMT
… as paclitaxel are among the standard chemotherapies for triple-negative breast cancer, one … , numerous processes can contribute to paclitaxel resistance. As a next-generation …
-
A pH/H2O2 Dual-Responsive Cobalt–Manganese-Based Nano-Delivery System for Chemo/Chemodynamic Therapy in Triple-Negative Breast Cancer
04 Nov 2025 20:24 GMT
… for treatment of breast cancer. Carbohydr. Polym. … of triple negative breast cancer. Nano Today. … paclitaxel prodrug with copper depletion for combined therapy toward triple-negative breast cancer … and chemodynamic therapy against breast tumors. Adv. Funct. …
About
© 1995-2025